3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
10
Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
SCLC,Extensive Stage
1
Rare Tumor
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Laryngeal Diseases
1
Hemangiosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor
1
Interventions
Gemcitabine
24
Cisplatin
24
durvalumab
13
pembrolizumab
9
Oxaliplatin
7
Capecitabine
7
Fluorouracil
6
Leucovorin
5
Bevacizumab
5
lenvatinib
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
Nivolumab
3
Liquid Biopsy
3
Injections
3
Folfox protocol
3
Carboplatin
3
zanidatamab
2
trifluridine tipiracil drug combination
2
tremelimumab
2
tislelizumab
2
ivosidenib
2
futibatinib
2
apatinib
2
Trastuzumab
2
Taxes
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Biliary Tract Neoplasms
×
niraparib
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled